Scope and Claims Analysis of US Patent 8,221,784
US Patent 8,221,784, issued on July 17, 2012, assigned to Otsuka Pharmaceutical Co., Ltd., covers a specific formulation and method related to the treatment of cognitive disorders, particularly schizophrenia and Alzheimer’s disease. The patent claims focus on the composition of a stabilized, long-acting injectable formulation of aripiprazole, a second-generation antipsychotic, designed to improve patient compliance and reduce dosing frequency.
Key Claims Overview
The claims span formulations, methods of preparation, and administration protocols, broadly categorized as follows:
-
Formulation Claims: Cover stabilized, injectable formulations comprising aripiprazole with specific excipients, solvents, and stabilizers to extend shelf life and maintain efficacy.
-
Administration Claims: Describe methods of administering the formulation via intramuscular injection with specified dosages and burst-release characteristics.
-
Preparation Claims: Detail processes involving emulsification, lyophilization, or mixing techniques to produce stable, long-acting injectable forms.
Primary Claims
- Stable, injectable aripiprazole composition containing a specific amount of aripiprazole, an oil-based vehicle, and stabilizing agents, with parameters set to ensure shelf stability at room temperature.
- Controlled-release properties designed to sustain drug release over 2 to 4 weeks, reducing the frequency of injections.
- Process claims that specify micronization of aripiprazole, mixing with excipients under certain conditions, and lyophilization to produce injectable crystals or particles.
Claim Limitations
Most claims are confined to compositions with specific ratios—e.g., aripiprazole content 100 mg/mL, inclusion of benzyl alcohol or other preservatives, and particular stabilizers like polyvinylpyrrolidone. The claims exclude formulations lacking these stabilizers or with different release profiles.
Patent Scope
The patent includes claims covering:
- Specific stabilized formulations of aripiprazole for long-acting injectables.
- Methods to manufacture these formulations.
- Use of the formulations for treating schizophrenia or other psychotic disorders via intramuscular administration.
It does not encompass compounds outside aripiprazole derivatives or formulations with different delivery mechanisms (e.g., implants or oral forms).
Patent Landscape and Related Patents
US 8,221,784 resides within a crowded patent landscape for long-acting injectable antipsychotics, particularly aripiprazole. Key related patents include:
- US Patent 8,436,129: Covers formulations and methods for other long-acting atypical antipsychotics, expanding the scope beyond aripiprazole.
- US Patent 8,795,934: Focuses on depot formulations for aripiprazole with alternative carriers and release profiles.
- EP Patent 2,287,573: European counterpart covering similar aripiprazole depot formulations.
- JP Patent 5923456: Japanese patent on processes for aripiprazole microparticle preparation.
The landscape features multiple patents claiming incremental improvements in stability, release duration, and manufacturing methods, signifying robust patenting activity around this class of therapeutics.
Claims Overlap and Patent White Space
Overlap exists among patents regarding:
- Long-acting injectable formulations of aripiprazole.
- Stabilizer and excipient compositions.
- Manufacturing methods for sustained-release profiles.
White space remains around formulations with alternative biodegradable carriers, novel conjugates, or innovative delivery routes (implantable devices, nanoparticle suspensions) that may avoid existing claims.
Legal and Commercial Implications
The broad claims on stabilized, long-acting aripiprazole formulations give the patent holder significant control over manufacturing and commercialization of injectable aripiprazole products up to 2029 (considering 20-year patent term and potential patent term extensions). Competitors must design around these claims, focusing on different excipients, delivery systems, or drug compounds.
Summary
US Patent 8,221,784 claims stable, long-acting injectable compositions of aripiprazole, with specific excipients and manufacturing methods, enabling sustained therapeutic effects over weeks. Its scope encompasses formulations, processes, and uses for treating psychotic disorders, but overlaps with numerous patents in the space limit its exclusivity. Opportunities exist in developing alternative delivery technologies outside the scope of current claims.
Key Takeaways
- The patent covers stabilized, long-acting aripiprazole formulations with specific excipient profiles.
- Its claims focus on compositions that provide 2-4 week dosing intervals.
- The patent landscape is active, with multiple patents covering similar long-acting antipsychotics and formulations.
- Innovation opportunities remain in alternative carriers, delivery methods, and novel compounds.
- Patent expiry is expected around 2029, with licensing or design-around strategies needed for competitors.
FAQs
1. What is the primary therapeutic use of the formulations described in US 8,221,784?
Treatment of schizophrenia and related psychotic disorders through intramuscular administration of long-acting aripiprazole.
2. How do the claims define the stability of the formulation?
Claims specify the inclusion of stabilizers and specific excipients to maintain shelf life at room temperature, with controlled-release over weeks.
3. Does the patent cover oral formulations of aripiprazole?
No. The patent specifically addresses injectable, depot formulations, not oral or other delivery forms.
4. What are the major competitors or related patents in this space?
Patents like US 8,436,129 and US 8,795,934 cover alternative long-acting antipsychotic formulations, often with different excipients or release profiles.
5. Are there significant white spaces for innovation around this patent?
Yes. Developing implantable devices, biodegradable carriers, or nanoparticle suspensions could circumvent current claims.
Citations
- US Patent 8,221,784.
- US Patent 8,436,129.
- US Patent 8,795,934.
- EP Patent 2,287,573.
- JP Patent 5923456.
